A Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to Ruxolitinib
September 11, 2026
A Phase 1 Study of IM-1021 in Participants with Advanced Malignancies